[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EP0437521A1 - Emulsion and use of the emulsion as a parenteral preparation - Google Patents

Emulsion and use of the emulsion as a parenteral preparation

Info

Publication number
EP0437521A1
EP0437521A1 EP89911781A EP89911781A EP0437521A1 EP 0437521 A1 EP0437521 A1 EP 0437521A1 EP 89911781 A EP89911781 A EP 89911781A EP 89911781 A EP89911781 A EP 89911781A EP 0437521 A1 EP0437521 A1 EP 0437521A1
Authority
EP
European Patent Office
Prior art keywords
emulsion
triglycerides
parenteral
triglyceride
glycerol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP89911781A
Other languages
German (de)
French (fr)
Inventor
Tomas Tage Hansen
Sven Erik Godtfredsen
Sven Froekjaer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8144235&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP0437521(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of EP0437521A1 publication Critical patent/EP0437521A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11C—FATTY ACIDS FROM FATS, OILS OR WAXES; CANDLES; FATS, OILS OR FATTY ACIDS BY CHEMICAL MODIFICATION OF FATS, OILS, OR FATTY ACIDS OBTAINED THEREFROM
    • C11C3/00—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom
    • C11C3/04—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom by esterification of fats or fatty oils
    • C11C3/10—Ester interchange
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
    • A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
    • A23D7/003—Compositions other than spreads
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/158—Fatty acids; Fats; Products containing oils or fats
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K40/00—Shaping or working-up of animal feeding-stuffs
    • A23K40/30—Shaping or working-up of animal feeding-stuffs by encapsulating; by coating
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/30—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with trihydroxylic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/587—Monocarboxylic acid esters having at least two carbon-to-carbon double bonds
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11C—FATTY ACIDS FROM FATS, OILS OR WAXES; CANDLES; FATS, OILS OR FATTY ACIDS BY CHEMICAL MODIFICATION OF FATS, OILS, OR FATTY ACIDS OBTAINED THEREFROM
    • C11C1/00—Preparation of fatty acids from fats, fatty oils, or waxes; Refining the fatty acids
    • C11C1/002—Sources of fatty acids, e.g. natural glycerides, characterised by the nature, the quantities or the distribution of said acids
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11C—FATTY ACIDS FROM FATS, OILS OR WAXES; CANDLES; FATS, OILS OR FATTY ACIDS BY CHEMICAL MODIFICATION OF FATS, OILS, OR FATTY ACIDS OBTAINED THEREFROM
    • C11C3/00—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom
    • C11C3/04—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom by esterification of fats or fatty oils
    • C11C3/08—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom by esterification of fats or fatty oils with fatty acids

Definitions

  • the invention relates to an emulsion and a use of the emulsion as a parenteral preparation.
  • the triglyceride 2-oleyl-1 , 3-dioctanoy1 glycerol (2[9-cis-octadecenoyl]-l,3-dioctanoyl glycerol) is described in Am. J. Clin. Nutr. 1987; 45:940-5 and the triglyceride 2-oleyl-l, 3-didecanoyl glycerol (2-[9-cis- octadecenoyl]-l,3-didecanoyl glycerol) is described in F. H. Mattson et al. , Journal of lipid research, 5, 374-77 (1964). Also, an emulsion for enteral use of the first mentioned of the above two triglycerides is described.
  • a very important clinical aspect in regard to the bioavailability is the slower metabolism in comparison to emulsions containing MCT, which are known to cause metabolic acidosis, when infused intravenously.
  • the emulsion according to the invention with an aqueous continuous phase and containing as the discontinous phase the triglyceride 2-oleyl-l,3-di(octanoyl/decanoyl) glycerol, is characterized by the fact that it is formulated for parenteral use. Any worker skilled in the art will know in principle how to compose such formulation.
  • 2-oleyl-l,3-di(octanoyl/decanoyl) glycerol encompasses both the pure 1,3-dioctanoyl triglyceride, the pure 1,3-didecanoyl triglyceride, and furthermore the l-octanoyl-3-decanoyl triglyceride and the 1- decanoyl-3-octanoyl triglyceride, the 2-position of course in all cases being occupied by oleic acid.
  • the emulsion according to the invention exhibits a better bioavailability than hitherto known parenteral emulsions used as a source for oleic acid.
  • the above-mentioned triglycerides turn out, surprisingly, to be very efficient sources of energy when applied in parenteral nutrition - the oleic acid moiety of the triglycerides being in an optimal position in the molecule in respect to their cleavage by lipoprotein lipase.
  • the above-mentioned triglycerides appear to exhibit physical properties which allow facile formulation of the compounds in liquid products as well as in powdered products exhibiting excellent wetability properties. In the liquid form the products of the invention possess excellent stabilities making sterilization of e.g. parenteral products containing the above triglycerides reliable, easy and safe.
  • triglycerides are advantageously applied in such emulsions due to their fast conversion by lipoprotein lipase and endothelial lipase and the consequential avoidance of the discomfort and side effects of lipolipaedemia.
  • Arachidonic acid applied in triglycerides of the invention are thus cleared quickly and efficiently thereby providing the essential fatty acid concomitantly with short chain acids useful as energy substrates.
  • a preferred embodiment of the emulsion according to the invention is characterized by the fact that the average diameter of the triglyceride globules is between 5 and 1000 nm, and that less than 5% of the triglyceride globules exhibits a diameter above 5000 nm.
  • This emulsion is well suited as a parenteral emulsion and shows a good bioavailability.
  • a preferred embodiment of the emulsion according to the invention is characterized by the fact that the average diameter of the triglyceride globules is between 5 and 1000 nm, that less than 5% of the triglyceride globules exhibits a diameter above 5000 nm, that the amount of the triglycerides in relation to the amount of the entire emulsion is between 2 and 30% by weight, and that the emulsion contains glycerol to isotonicity and 0.2 - 10% by weight of an emulsifier.
  • This emulsion is very well suited as a parenteral emulsion and shows a superior absorption ability.
  • a preferred emulsifier is a phospholipid.
  • triglycerides in parenteral nutritional products is further particularly advantageous since the relatively high polarity of the triglycerides favour the stability of their emulsions which are subjected to severe heat treatments during their manufacturing. Use of such emulsion is particularly advantageous for nutrition of severely ill patients e.g. post-operatively.
  • a preferred embodiment of the emulsion according to the invention is characterized by the fact that the triglycerides have a purity of at least 30%, preferably at least 50%, more preferably at least 75%, and most preferably at least 90%. The higher the purity of the triglyceride, the more efficient the absorption of the triglyceride.
  • the invention comprises a use of the emulsion according to the invention as a parenteral preparation.
  • a parenteral feeding product was prepared according to the following formula:
  • Fianlly water (IV) was added to a total volume of 1000 ml. The whole mixture was further prehomogenized for another 2-3 minutes (ultra turrax) . The pre-emulsion was homogenized in a high pressure homogenizer (MHO Microfluidizer, Microfluidics Corporation, Newton, Mass.). The product was processed 5 times through the Microfluidizer. In order to keep the product temperature below 20 ⁇ C the product was passed through an ice slurry by each cycle. The oxidation of lipids was prevented by running the process under Argon and by using liquids saturated with Argon. The product was filled in a suitable package and sterilized in an autoclave at 120°C for 20 minutes.
  • MHO Microfluidizer Microfluidics Corporation, Newton, Mass.
  • the superiority of the compounds of the invention was illustrated by comparing the rate of their hydrolysis by lipoprotein lipase with the rate of hydrolysis of the non- structured lipid (LLL) and the commercial product Intralipid which contains long chain fatty acids at all positions of the triglyceride molecules. All emulsions were made as described in Example 1. As is apparent from the table below the structured lipid was hydrolyzed at an increased rate thus offering advantages as mentioned above.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Animal Husbandry (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Fats And Perfumes (AREA)

Abstract

L'émulsion comporte une phase aqueuse continue et contient à titre de phase discontinue les triglycérides 2-oleyl-1,3-di(octanoyl/décanoyl), formulés pour une utilisation parentérale. Cette émulsion présente une meilleure biodisponibilité que les émulsions parentérales connues à ce jour qui sont utilisées comme source d'acide oléique.The emulsion comprises a continuous aqueous phase and contains, as a discontinuous phase, the 2-oleyl-1,3-di (octanoyl / decanoyl) triglycerides, formulated for parenteral use. This emulsion has better bioavailability than the parenteral emulsions known to date which are used as a source of oleic acid.

Description

EMULSION AND USE OF THE EMULSION AS A PARENTERAL PREPARATION
The invention relates to an emulsion and a use of the emulsion as a parenteral preparation.
The triglyceride 2-oleyl-1 , 3-dioctanoy1 glycerol (2[9-cis-octadecenoyl]-l,3-dioctanoyl glycerol) is described in Am. J. Clin. Nutr. 1987; 45:940-5 and the triglyceride 2-oleyl-l, 3-didecanoyl glycerol (2-[9-cis- octadecenoyl]-l,3-didecanoyl glycerol) is described in F. H. Mattson et al. , Journal of lipid research, 5, 374-77 (1964). Also, an emulsion for enteral use of the first mentioned of the above two triglycerides is described.
As the above triglycerides are important as nutrients, especially for diseased humans, there is a need for an emulsion of 2-oleyl-l, 3-di(octanoyl/decanoyl) glycerol, which can be used for parenteral nutrition, and which exhibits a better bioavailability than hitherto known parenteral emulsions used as a source for oleic acid.
A very important clinical aspect in regard to the bioavailability is the slower metabolism in comparison to emulsions containing MCT, which are known to cause metabolic acidosis, when infused intravenously.
The emulsion according to the invention with an aqueous continuous phase and containing as the discontinous phase the triglyceride 2-oleyl-l,3-di(octanoyl/decanoyl) glycerol, is characterized by the fact that it is formulated for parenteral use. Any worker skilled in the art will know in principle how to compose such formulation. It is to be understood that the term 2-oleyl-l,3-di(octanoyl/decanoyl) glycerol encompasses both the pure 1,3-dioctanoyl triglyceride, the pure 1,3-didecanoyl triglyceride, and furthermore the l-octanoyl-3-decanoyl triglyceride and the 1- decanoyl-3-octanoyl triglyceride, the 2-position of course in all cases being occupied by oleic acid.
Surprisingly it has been found that the emulsion according to the invention exhibits a better bioavailability than hitherto known parenteral emulsions used as a source for oleic acid. Moreover, the above-mentioned triglycerides turn out, surprisingly, to be very efficient sources of energy when applied in parenteral nutrition - the oleic acid moiety of the triglycerides being in an optimal position in the molecule in respect to their cleavage by lipoprotein lipase. surprisingly, the above-mentioned triglycerides appear to exhibit physical properties which allow facile formulation of the compounds in liquid products as well as in powdered products exhibiting excellent wetability properties. In the liquid form the products of the invention possess excellent stabilities making sterilization of e.g. parenteral products containing the above triglycerides reliable, easy and safe.
The above-mentioned triglycerides are advantageously applied in such emulsions due to their fast conversion by lipoprotein lipase and endothelial lipase and the consequential avoidance of the discomfort and side effects of lipolipaedemia. Arachidonic acid applied in triglycerides of the invention are thus cleared quickly and efficiently thereby providing the essential fatty acid concomitantly with short chain acids useful as energy substrates.
A preferred embodiment of the emulsion according to the invention is characterized by the fact that the average diameter of the triglyceride globules is between 5 and 1000 nm, and that less than 5% of the triglyceride globules exhibits a diameter above 5000 nm. This emulsion is well suited as a parenteral emulsion and shows a good bioavailability. A preferred embodiment of the emulsion according to the invention is characterized by the fact that the average diameter of the triglyceride globules is between 5 and 1000 nm, that less than 5% of the triglyceride globules exhibits a diameter above 5000 nm, that the amount of the triglycerides in relation to the amount of the entire emulsion is between 2 and 30% by weight, and that the emulsion contains glycerol to isotonicity and 0.2 - 10% by weight of an emulsifier. This emulsion is very well suited as a parenteral emulsion and shows a superior absorption ability. A preferred emulsifier is a phospholipid.
The use of the above-mentioned triglycerides in parenteral nutritional products is further particularly advantageous since the relatively high polarity of the triglycerides favour the stability of their emulsions which are subjected to severe heat treatments during their manufacturing. Use of such emulsion is particularly advantageous for nutrition of severely ill patients e.g. post-operatively.
A preferred embodiment of the emulsion according to the invention is characterized by the fact that the triglycerides have a purity of at least 30%, preferably at least 50%, more preferably at least 75%, and most preferably at least 90%. The higher the purity of the triglyceride, the more efficient the absorption of the triglyceride.
Also the invention comprises a use of the emulsion according to the invention as a parenteral preparation.
EXAMPLE 1
A parenteral feeding product was prepared according to the following formula:
Composition for 1000 ml
I Lipid 100.0 g II Egg yolk phospholipids (Lipoid E80) 12.0 g
III Glycerol 22.5 g
IV Water for injection to 1000 ml
Production Procedure
II was dispersed in 500 ml of IV by a high shear mixer (Ultra turrax) followed by the addition of I and III..
Fianlly water (IV) was added to a total volume of 1000 ml. The whole mixture was further prehomogenized for another 2-3 minutes (ultra turrax) . The pre-emulsion was homogenized in a high pressure homogenizer (MHO Microfluidizer, Microfluidics Corporation, Newton, Mass.). The product was processed 5 times through the Microfluidizer. In order to keep the product temperature below 20βC the product was passed through an ice slurry by each cycle. The oxidation of lipids was prevented by running the process under Argon and by using liquids saturated with Argon. The product was filled in a suitable package and sterilized in an autoclave at 120°C for 20 minutes.
Analytical data
pH = 6.5
Osmolality = 285 mOsm/kg water Particle size (d2) = 300 nm Limulus test = < 4 EU/ml
EXAMPLE 2
The superiority of the compounds of the invention was illustrated by comparing the rate of their hydrolysis by lipoprotein lipase with the rate of hydrolysis of the non- structured lipid (LLL) and the commercial product Intralipid which contains long chain fatty acids at all positions of the triglyceride molecules. All emulsions were made as described in Example 1. As is apparent from the table below the structured lipid was hydrolyzed at an increased rate thus offering advantages as mentioned above.

Claims

1. An emulsion with an aqueous, continuous phase and containing as the discontinuous phase the triglycerides 2- oleyl-1,3-di(octanoyl/decanoyl) glycerol, formulated for parenteral use.
2. An emulsion according to Claim 1, wherein the average diameter of the triglyceride globules is between 5 and 1000 nm, and wherein less than 5% of the triglyceride globules exhibits a diameter above 5000 nm.
3. An emulsion according to Claim 2, wherein the amount of the triglycerides in relation to the amount of the entire emulsion is between 2 and 30% by weight, and the emulsion contains glycerol to isotonicity and 0.2 - 10% by weight of an emulsifier.
4. Emulsion according to Claims 1 - 3, wherein the triglycerides have a purity of at least 30%, preferably at least 50%, more preferably at least 75%, and most preferably at least 90%.
5. Use of the emulsion according to Claims 1 - 4, as a parenteral preparation.
EP89911781A 1988-10-10 1989-10-10 Emulsion and use of the emulsion as a parenteral preparation Withdrawn EP0437521A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK5652/88 1988-10-10
DK565288A DK565288D0 (en) 1988-10-11 1988-10-11 PROCEDURE FOR THE PREPARATION OF TRIGLYCERIDES, APPLICATION OF SUCH TRIGLYCERIDES, AND AN EMULSION CONTAINING SUCH TRIGLYCERIDES

Publications (1)

Publication Number Publication Date
EP0437521A1 true EP0437521A1 (en) 1991-07-24

Family

ID=8144235

Family Applications (8)

Application Number Title Priority Date Filing Date
EP89911784A Expired - Lifetime EP0437523B1 (en) 1988-10-10 1989-10-10 Triglycerides, nutritional composition comprising such triglycerides, and use of the nutritional composition for nutrition
EP89911782A Withdrawn EP0437522A1 (en) 1988-10-10 1989-10-10 Emulsion and use of the emulsion as a parenteral preparation
EP89911785A Expired - Lifetime EP0437524B1 (en) 1988-10-10 1989-10-10 Triglyceride and nutritional composition comprising such triglycerides.
EP89911778A Expired - Lifetime EP0437518B1 (en) 1988-10-10 1989-10-10 Triglycerides and composition comprising such triglycerides
EP89911781A Withdrawn EP0437521A1 (en) 1988-10-10 1989-10-10 Emulsion and use of the emulsion as a parenteral preparation
EP89911783A Expired - Lifetime EP0438483B1 (en) 1988-10-10 1989-10-10 Triglycerides and nutritional composition comprising such triglycerides
EP89911779A Expired - Lifetime EP0437519B1 (en) 1988-10-10 1989-10-10 Triglycerides and nutritional composition comprising such triglycerides.
EP89911780A Expired - Lifetime EP0437520B1 (en) 1988-10-10 1989-10-10 Triglyceride and nutritional composition comprising such triglyceride

Family Applications Before (4)

Application Number Title Priority Date Filing Date
EP89911784A Expired - Lifetime EP0437523B1 (en) 1988-10-10 1989-10-10 Triglycerides, nutritional composition comprising such triglycerides, and use of the nutritional composition for nutrition
EP89911782A Withdrawn EP0437522A1 (en) 1988-10-10 1989-10-10 Emulsion and use of the emulsion as a parenteral preparation
EP89911785A Expired - Lifetime EP0437524B1 (en) 1988-10-10 1989-10-10 Triglyceride and nutritional composition comprising such triglycerides.
EP89911778A Expired - Lifetime EP0437518B1 (en) 1988-10-10 1989-10-10 Triglycerides and composition comprising such triglycerides

Family Applications After (3)

Application Number Title Priority Date Filing Date
EP89911783A Expired - Lifetime EP0438483B1 (en) 1988-10-10 1989-10-10 Triglycerides and nutritional composition comprising such triglycerides
EP89911779A Expired - Lifetime EP0437519B1 (en) 1988-10-10 1989-10-10 Triglycerides and nutritional composition comprising such triglycerides.
EP89911780A Expired - Lifetime EP0437520B1 (en) 1988-10-10 1989-10-10 Triglyceride and nutritional composition comprising such triglyceride

Country Status (8)

Country Link
EP (8) EP0437523B1 (en)
JP (8) JPH04500972A (en)
AU (8) AU640353B2 (en)
CA (8) CA2000395A1 (en)
DE (1) DE68909053T2 (en)
DK (1) DK565288D0 (en)
WO (8) WO1990004011A1 (en)
ZA (2) ZA897693B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK565288D0 (en) * 1988-10-11 1988-10-11 Novo Industri As PROCEDURE FOR THE PREPARATION OF TRIGLYCERIDES, APPLICATION OF SUCH TRIGLYCERIDES, AND AN EMULSION CONTAINING SUCH TRIGLYCERIDES
WO1992015283A1 (en) * 1991-03-01 1992-09-17 Novo Nordisk A/S Parenteral emulsion
DE69420124T2 (en) * 1993-01-15 2000-03-02 Abbott Laboratories, Abbott Park STRUCTURED LIPIDS
US5574065A (en) * 1994-04-21 1996-11-12 Clintec Nutrition Co. Method and composition for normalizing injury response
US5589468A (en) * 1995-01-13 1996-12-31 Clintec Nutrition Co. Method for providing nutrition to elderly patients
EP0739590B1 (en) 1995-04-28 2001-06-13 Loders Croklaan B.V. Triglycerides, rich in polyunsaturated fatty acids
US5993221A (en) * 1997-05-01 1999-11-30 Beth Israel Deaconess Medical Center, Inc. Dietary formulation comprising arachidonic acid and methods of use
IT1292126B1 (en) 1997-06-11 1999-01-25 Guido Galliani WAX ESTERS ENRICHED IN UNSATURATED OMEGA-3 FATTY ACIDS, THEIR PREPARATION AND USE
DK0893064T3 (en) * 1997-07-22 2003-04-22 Nestle Sa Lipid composition for infant formulas as well as their preparation method
WO2003033632A1 (en) 2001-10-18 2003-04-24 Council Of Scientific And Industrial Research Cholesterol lowering structured lipids with omega 6 pufa
EP2324828A1 (en) * 2003-08-18 2011-05-25 BTG International Limited Treatment for neurodegenerative conditions
EP3251518A4 (en) * 2015-01-26 2018-09-05 The Nisshin OilliO Group, Ltd. Oil or fat
EP3750533A4 (en) 2018-02-09 2021-11-03 Nippon Suisan Kaisha, Ltd. Agent for improving lymphatic circulation
KR20210077697A (en) * 2018-10-15 2021-06-25 엠.에이. 메드 얼라이언스 에스에이 Coatings for endoluminal expandable catheters providing contact delivery of drug micro-reservoirs

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2515174A1 (en) 1981-10-23 1983-04-29 Roussel Uclaf NOVEL TRIGLYCERIDES, PROCESS FOR THE PREPARATION AND APPLICATIONS IN DIETETICS AND THERAPEUTICS
US4701468A (en) * 1983-04-15 1987-10-20 Roussel-Uclaf Oxidized triglycerides having therapeutic utility
US4701469A (en) * 1983-04-15 1987-10-20 Roussel Uclaf Triglycerides, process for therapeutical applications and compositions containing them
US4607052A (en) * 1983-04-15 1986-08-19 Roussel-Uclaf Triglycerides, dietetic and therapeutical applications and compositions containing them
US4753963A (en) * 1985-09-26 1988-06-28 The Procter & Gamble Company Nutritional fat suitable for enteral and parenteral products
JPS6387988A (en) * 1986-10-01 1988-04-19 Nisshin Oil Mills Ltd:The Oil and fat having excellent digestibility and absorbability
JPS63297342A (en) * 1987-05-28 1988-12-05 Nisshin Oil Mills Ltd:The Synthetic oil or fat and fatty emulsion infusion solution and tube feeding agent containing said oil or fat
DK565288D0 (en) * 1988-10-11 1988-10-11 Novo Industri As PROCEDURE FOR THE PREPARATION OF TRIGLYCERIDES, APPLICATION OF SUCH TRIGLYCERIDES, AND AN EMULSION CONTAINING SUCH TRIGLYCERIDES

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9003787A1 *

Also Published As

Publication number Publication date
WO1990004009A1 (en) 1990-04-19
DK565288D0 (en) 1988-10-11
EP0438483B1 (en) 1992-04-15
JPH04501116A (en) 1992-02-27
AU640353B2 (en) 1993-08-26
JPH04501113A (en) 1992-02-27
WO1990004008A1 (en) 1990-04-19
JPH04501115A (en) 1992-02-27
EP0437522A1 (en) 1991-07-24
CA2000398A1 (en) 1990-04-10
WO1990003786A1 (en) 1990-04-19
WO1990004012A1 (en) 1990-04-19
EP0437518B1 (en) 1992-04-15
WO1990004010A1 (en) 1990-04-19
EP0437520A1 (en) 1991-07-24
CA2000391A1 (en) 1990-04-10
EP0437523B1 (en) 1993-09-08
WO1990003787A1 (en) 1990-04-19
AU636582B2 (en) 1993-05-06
AU4420589A (en) 1990-05-01
JPH04500972A (en) 1992-02-20
AU4422289A (en) 1990-05-01
DE68909053D1 (en) 1993-10-14
ZA897693B (en) 1990-06-27
WO1990004013A1 (en) 1990-04-19
AU630120B2 (en) 1992-10-22
AU4421989A (en) 1990-05-01
CA2000393A1 (en) 1990-04-10
JPH04501114A (en) 1992-02-27
AU4422089A (en) 1990-05-01
CA2000396A1 (en) 1990-04-10
AU4420489A (en) 1990-05-01
EP0437520B1 (en) 1992-04-15
JPH04500971A (en) 1992-02-20
EP0437524B1 (en) 1992-04-15
EP0437519A1 (en) 1991-07-24
CA2000394A1 (en) 1990-04-10
AU4421089A (en) 1990-05-01
ZA897692B (en) 1990-06-27
EP0438483A1 (en) 1991-07-31
CA2000397A1 (en) 1990-04-10
AU639675B2 (en) 1993-08-05
AU631816B2 (en) 1992-12-10
JPH04500974A (en) 1992-02-20
WO1990004011A1 (en) 1990-04-19
AU4422489A (en) 1990-05-01
AU4421189A (en) 1990-05-01
EP0437524A1 (en) 1991-07-24
AU629866B2 (en) 1992-10-15
CA2000395A1 (en) 1990-04-10
EP0437518A1 (en) 1991-07-24
EP0437519B1 (en) 1992-04-15
DE68909053T2 (en) 1994-01-05
EP0437523A1 (en) 1991-07-24
CA2000392A1 (en) 1990-04-10
JPH04500973A (en) 1992-02-20

Similar Documents

Publication Publication Date Title
EP0437521A1 (en) Emulsion and use of the emulsion as a parenteral preparation
US4684633A (en) Phospholipid-emulsified prostaglandin composition
JP2704922B2 (en) Fatty acid composition
US7560486B2 (en) Composition and method for modifying the fatty acid composition of cell membranes of organs and tissues
Chen et al. Digestion, absorption and effects on cholesterol absorption of menhaden oil, fish oil concentrate and corn oil by rats
JPS61502816A (en) Diet supplements and methods to minimize infectious effects through diet
JP2001505762A (en) Dietary foods containing conjugated linoleic acid
CA2625338A1 (en) Salts of fatty acids and methods of making and using thereof
JP4165904B2 (en) Hydrolysis optimized lipid emulsion and use thereof
ES2551680T3 (en) Conjugated Linoleic Acid Compositions
Driscoll Pharmaceutical and clinical aspects of lipid injectable emulsions
JP4008965B2 (en) Preparation of lecithin-containing fat emulsion
Taraszewski et al. N-6 fatty acids
WO2015138224A1 (en) Compositions and methods for reducing chronic low-level inflammation
JP3611130B2 (en) Preparation method of fat emulsion
JPH0224396A (en) Production of concentrated fish oil fatty acid/alpha-amino acid derivative and transfusion containing the same
JP2001064171A (en) Deconjugate protein expression inducing agent
JPH03153628A (en) Solubilized composition of highly unsaturated fatty acid-containing lipid
Ceola Sucrose stearate as food-grade stabilizer for lipid-based nanoparticles: characterization of the internal structure and time stability of eicosapentaenoic acid loaded mesosomes
JP6018712B2 (en) Absorption accelerator for unsaturated fatty acids
JP2000086521A (en) Antiallergic composition for oral administration

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19910405

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17Q First examination report despatched

Effective date: 19911202

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 19920316